0 CHECKOUT

Refractory Multiple Myeloma - Pipeline Review, H2 2015

  • ID: 3492380
  • September 2015
  • 463 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • Astellas Pharma Inc.
  • Cleave Biosciences
  • F. Hoffmann-La Roche Ltd.
  • MedImmune, LLC
  • Oncolytics Biotech Inc.
  • MORE

Refractory Multiple Myeloma - Pipeline Review, H2 2015

Summary

The report ‘Refractory Multiple Myeloma - Pipeline Review, H2 2015’, provides an overview of the Refractory Multiple Myeloma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • Astellas Pharma Inc.
  • Cleave Biosciences
  • F. Hoffmann-La Roche Ltd.
  • MedImmune, LLC
  • Oncolytics Biotech Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Refractory Multiple Myeloma Overview

Therapeutics Development

Pipeline Products for Refractory Multiple Myeloma - Overview

Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis

Refractory Multiple Myeloma - Therapeutics under Development by Companies

Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes

Refractory Multiple Myeloma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Refractory Multiple Myeloma - Products under Development by Companies

Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes

Refractory Multiple Myeloma - Companies Involved in Therapeutics Development

4SC AG

AbbVie Inc.

Acetylon Pharmaceuticals, Inc.

Altor BioScience Corporation

Arno Therapeutics, Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

Biotest AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Celgene Corporation

Cellectar Biosciences, Inc.

Cleave Biosciences

CureTech Ltd.

Curis, Inc.

Dicerna Pharmaceuticals, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Immunomedics, Inc.

Jasco Pharmaceuticals, LLC.

Johnson & Johnson

JW Pharmaceutical Corporation

Karyopharm Therapeutics, Inc.

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

MorphoSys AG

Novartis AG

Oncolytics Biotech Inc.

Oncopeptides AB

Onyx Pharmaceuticals, Inc.

Otsuka Holdings Co., Ltd.

Patrys Limited

Pfizer Inc.

Pharma Mar, S.A.

Prolexys Pharmaceuticals, Inc.

Sanofi

Sigma-Tau S.p.A.

Stemline Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Synta Pharmaceuticals Corp.

Threshold Pharmaceuticals, Inc.

Vivolux AB

Refractory Multiple Myeloma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

4SC-202 - Drug Profile

ABBV-838 - Drug Profile

ACP-196 - Drug Profile

ACY-241 - Drug Profile

afuresertib hydrochloride - Drug Profile

alisertib - Drug Profile

alpelisib - Drug Profile

ALT-801 - Drug Profile

ALT-803 - Drug Profile

amrubicin hydrochloride - Drug Profile

AR-42 - Drug Profile

AT-7519 - Drug Profile

AT-9283 - Drug Profile

B-701 - Drug Profile

bendamustine hydrochloride - Drug Profile

BI-836909 - Drug Profile

BMS-986016 - Drug Profile

cabozantinib s-malate - Drug Profile

carfilzomib - Drug Profile

CB-5083 - Drug Profile

CB-839 - Drug Profile

CC-90002 - Drug Profile

Cell Therapy to Target CD138 for Relapsed and Refractory Multiple Myeloma - Drug Profile

CUDC-907 - Drug Profile

CWP-291 - Drug Profile

daratumumab - Drug Profile

DCRM-1711 - Drug Profile

DKN-01 - Drug Profile

elotuzumab - Drug Profile

erismodegib - Drug Profile

evofosfamide - Drug Profile

filanesib - Drug Profile

ganetespib - Drug Profile

GSK-2857916 - Drug Profile

I131-CLR1404 - Drug Profile

ibrutinib - Drug Profile

indatuximab ravtansine - Drug Profile

inebilizumab - Drug Profile

ipilimumab - Drug Profile

isatuximab - Drug Profile

ixazomib citrate - Drug Profile

JP-11646 - Drug Profile

LCL-161 - Drug Profile

linsitinib - Drug Profile

marizomib - Drug Profile

Melflufen - Drug Profile

milatuzumab - Drug Profile

MOR-202 - Drug Profile

MV-NIS - Drug Profile

NL-101 - Drug Profile

OPB-51602 - Drug Profile

oprozomib - Drug Profile

palbociclib - Drug Profile

PATSM-6 - Drug Profile

pelareorep - Drug Profile

pembrolizumab - Drug Profile

pidilizumab - Drug Profile

PIM-447 - Drug Profile

plerixafor - Drug Profile

plitidepsin - Drug Profile

PRLX-93936 - Drug Profile

Recombinant Protein for Oncology - Drug Profile

ricolinostat - Drug Profile

roneparstat - Drug Profile

RRX-001 - Drug Profile

sapanisertib - Drug Profile

selinexor - Drug Profile

SL-401 - Drug Profile

trametinib dimethyl sulfoxide + uprosertib - Drug Profile

ulocuplumab - Drug Profile

urelumab - Drug Profile

vemurafenib - Drug Profile

venetoclax - Drug Profile

VLX-1570 - Drug Profile

vorinostat - Drug Profile

Refractory Multiple Myeloma - Recent Pipeline Updates

Refractory Multiple Myeloma - Dormant Projects

Refractory Multiple Myeloma - Discontinued Products

Refractory Multiple Myeloma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Refractory Multiple Myeloma, H2 2015

Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Development by Companies, H2 2015 (Contd..1)

Number of Products under Development by Companies, H2 2015 (Contd..2)

Number of Products under Development by Companies, H2 2015 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Development by Companies, H2 2015 (Contd..3)

Products under Development by Companies, H2 2015 (Contd..4)

Products under Investigation by Universities/Institutes, H2 2015

Refractory Multiple Myeloma - Pipeline by 4SC AG, H2 2015

Refractory Multiple Myeloma - Pipeline by AbbVie Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Altor BioScience Corporation, H2 2015

Refractory Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Array BioPharma Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Astellas Pharma Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Biotest AG, H2 2015

Refractory Multiple Myeloma - Pipeline by Boehringer Ingelheim GmbH, H2 2015

Refractory Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H2 2015

Refractory Multiple Myeloma - Pipeline by Calithera Biosciences, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Celgene Corporation, H2 2015

Refractory Multiple Myeloma - Pipeline by Cellectar Biosciences, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Cleave Biosciences, H2 2015

Refractory Multiple Myeloma - Pipeline by CureTech Ltd., H2 2015

Refractory Multiple Myeloma - Pipeline by Curis, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Exelixis, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015

Refractory Multiple Myeloma - Pipeline by GlaxoSmithKline Plc, H2 2015

Refractory Multiple Myeloma - Pipeline by Immunomedics, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015

Refractory Multiple Myeloma - Pipeline by Johnson & Johnson, H2 2015

Refractory Multiple Myeloma - Pipeline by JW Pharmaceutical Corporation, H2 2015

Refractory Multiple Myeloma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by MedImmune, LLC, H2 2015

Refractory Multiple Myeloma - Pipeline by Merck & Co., Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by MorphoSys AG, H2 2015

Refractory Multiple Myeloma - Pipeline by Novartis AG, H2 2015

Refractory Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Oncopeptides AB, H2 2015

Refractory Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Otsuka Holdings Co., Ltd., H2 2015

Refractory Multiple Myeloma - Pipeline by Patrys Limited, H2 2015

Refractory Multiple Myeloma - Pipeline by Pfizer Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Pharma Mar, S.A., H2 2015

Refractory Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Sanofi, H2 2015

Refractory Multiple Myeloma - Pipeline by Sigma-Tau S.p.A., H2 2015

Refractory Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015

Refractory Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H2 2015

Refractory Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015

Refractory Multiple Myeloma - Pipeline by Vivolux AB, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Refractory Multiple Myeloma Therapeutics - Recent Pipeline Updates, H2 2015

Refractory Multiple Myeloma - Dormant Projects, H2 2015

Refractory Multiple Myeloma - Dormant Projects (Contd..1), H2 2015

Refractory Multiple Myeloma - Dormant Projects (Contd..2), H2 2015

Refractory Multiple Myeloma - Dormant Projects (Contd..3), H2 2015

Refractory Multiple Myeloma - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Refractory Multiple Myeloma, H2 2015

Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

4SC AG
AbbVie Inc.
Acetylon Pharmaceuticals, Inc.
Altor BioScience Corporation
Arno Therapeutics, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Biotest AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cellectar Biosciences, Inc.
Cleave Biosciences
CureTech Ltd.
Curis, Inc.
Dicerna Pharmaceuticals, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Immunomedics, Inc.
Jasco Pharmaceuticals, LLC.
Johnson & Johnson
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
MedImmune, LLC
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Novartis AG
Oncolytics Biotech Inc.
Oncopeptides AB
Onyx Pharmaceuticals, Inc.
Otsuka Holdings Co., Ltd.
Patrys Limited
Pfizer Inc.
Pharma Mar, S.A.
Prolexys Pharmaceuticals, Inc.
Sanofi
Sigma-Tau S.p.A.
Stemline Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synta Pharmaceuticals Corp.
Threshold Pharmaceuticals, Inc.
Vivolux AB

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)